ArticleInternational journal of breast cancer2026
Artificial Intelligence as an Assistive Tool in Breast Cancer Screening and Diagnosis in the Digital Era.
Article in International journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Breast cancer (BC) is a worldwide health task, and its increasing frequency and the associated burden on healthcare professionals are also increasing. Hence, integrating machine learning (ML) and artificial intelligence (AI) into screening and diagnosis is irrefutable in the digital age. A comprehensive systematic review was conducted aimed at assessing the application of AI and ML techniques to enhance BC screening, diagnosis, classification, and tumor marker scoring. Methods: An electronic literature search in PubMed and google scholar by following systematic review guidelines was conducted using keywords AI, cytology, histology, tumor marker expression, deep learning (DL) and ML and carcinoma breast. Articles exclusively pertaining to BC pathology were included in the study. Results: This study reviews the AI tools incorporating advanced DL models, such as artificial neural networks (ANNs), support vector machines (SVMs), convolutional neural networks (CNNs), and faster R-CNN, which have demonstrated high accuracy in analyzing medical images from various modalities, including cytology and histopathology. AI applications also extend to combined imaging-pathology diagnostics and tumor biomarkers, showing promising outcomes for consistency, rapidity, and cost-effectiveness. Various Food and Drug Administration (FDA) and internationally approved AI software products for BC detection illustrate the translation potential of these technologies. Conclusions: The use of AI in the analysis of pathological samples in diagnosis, research, precision medicine, and patient care is increasing, and such assistance has great potential to reduce the workload of pathologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.